Edwards Lifesciences Corp reports $6.07 billion revenue for fiscal year ended December 31, 2025, up 11.5%
Edwards Lifesciences Corp reported revenue of $6.07 billion for the year ended December 31, 2025, an increase of 11.5% from the previous year ($5.44 billion).
For the same period it posted net income of $1.07 billion, down 74.3%, or $1.83 per diluted share (6.97 a year earlier).
That is a net margin of 17.7%.
On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).
Is Edwards Lifesciences Corp halal?
See the full AAOIFI screening of Edwards Lifesciences Corp
See the full AAOIFI screening of Edwards Lifesciences Corp
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.